These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9133451)

  • 1. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
    Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
    Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
    Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
    Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
    Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
    Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement.
    Bohn U; Aguiar J; Bilbao C; Murias A; Vega V; Chirino R; Díaz-Chico N; Díaz-Chico JC
    Int J Cancer; 2002 Oct; 101(6):539-44. PubMed ID: 12237894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].
    Ruibal A; Arias J; Del Río MC; Resino C; Tejerina A
    Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
    Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
    Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
    Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
    Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
    Ruibal A; Garrido-Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.